Pernix Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Morristown NJ United States (1996)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2009
NCT01086358
First Marketed Drug
2008
sumatriptan (zecuity)
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PERNIX | PERNIX IRELAND LTD | PERNIX IRELAND PAIN | Pernix Theraputics LLC

Active Ingredients

Marketed Drugs (5)

acetaminophen (tylenol) (2016)

doxepin (sinequan) (2010)

hydrocodone (hycodan) (2013)

naproxen (naprosyn) (2008)

sumatriptan (zecuity) (2008)

Drugs in Phase 4 Trials (4)

doxepin (sinequan) (1 trial)

naproxen (naprosyn) (1 trial)

sumatriptan (zecuity) (1 trial)

zolpidem (ambien) (1 trial)

Drugs in Phase 3 Trials (1)

Key: Pernix (0) Acquired (1)

nalmefene (revex) (2 trials)

Drugs in Phase 2 Trials (2)

antipyrine (1 trial)

benzocaine (Orajel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 4)

Migraine Disorders (Phase 4)

Otitis (Phase 2)

Otitis Media (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7